Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $336.94M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.73M
Average 0.81M
IRD Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Opus Genetics, Inc.NASDAQ: IRD
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -3038.2%
Net margin was -3038.2% in Q1 FY2026, down 2850.7 pp from a year earlier. On a trailing-twelve-month basis it was -892.4%, down 462.9 pp year over year. Over 3 fiscal years it narrowed by 394.2 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 13 analysts of -551.2% for the fiscal year ending Dec 2026, down from -349.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -3038.2%-2610.7 pp QoQ
- Last fiscal yearDec 2025
- -349.3%+174.1 pp YoY
- LTMMar 2026
- -892.4%-462.9 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -349.3%
- Year-over-year change
- +174.1pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -349.3% | +174.1pp |
| FY2024 | 2024-12-31 | -523.4% | -471.0pp |
| FY2023 | 2023-12-31 | -52.4% | -97.3pp |
| FY2022 | 2022-12-31 | 44.9% | +9670.2pp |
| FY2021 | 2021-12-31 | -9625.3% | — |
Net Margin vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 net margin of -892.4% is the 4th highest of the 6 companies compared; the peer median is -680.8%.
- Its year-over-year change of -462.9 pp is the 3rd highest of 5, against a peer median of -221.9 pp.
- Over three fiscal years its change of -394.2 pp compares with a peer median of -201.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 52.2% | +243.7 pp | +224.6 pp | |
| LTM Mar 2026 | -468.7% | +97.4 pp | +176.5 pp | |
| LTM Mar 2026 | -680.8% | -541.1 pp | -579.4 pp | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -892.4% | -462.9 pp | -394.2 pp |
| LTM Mar 2026 | -4088.8% | — | — | |
| FY2025 | -130000.0% | -80745.7 pp | -127273.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding IRD) | -680.8% | -221.9 pp | -201.5 pp | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 15.17M | 14.36M | 17.65M | 26.85M | 30.81M |
| Selling, General & Admin | 8.12M | 7.27M | 11.96M | 18.22M | 21.98M |
| Operating Expenses | 23.29M | 21.62M | 29.61M | 73.07M | 52.8M |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| EBITDA | (56.69M) | 18.22M | (9.97M) | (57.52M) | (48.07M) |
| EBITDA Margin | -9624.3% | 45.7% | -52.3% | -523.3% | -338.6% |
| Operating Income | (22.71M) | 18.23M | (10.56M) | (62.07M) | (38.6M) |
| Operating Margin | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2K | 9K | 1.33M | 0 | 1.47M |
| Other Income / Expenses | (33.99M) | (23K) | 589K | 4.54M | (10.99M) |
| Income Before Tax | (56.69M) | 18.2M | (9.97M) | (57.53M) | (49.59M) |
| Pre-Tax Margin | -9625.3% | 45.7% | -52.4% | -523.4% | -349.3% |
| Income Tax Expense | 0 | 315K | 12K | 0 | 0 |
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Net Margin | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (Basic) | (3.82) | 0.90 | (0.46) | (2.15) | (0.80) |
| EPS (Diluted) | (3.82) | 0.87 | (0.46) | (2.15) | (0.80) |
| Weighted Avg Shares | 14.85M | 19.93M | 21.59M | 26.72M | 622.22M |
| Weighted Avg Shares (Diluted) | 14.85M | 20.6M | 21.59M | 26.72M | 622.22M |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$4.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.